Company: CERO
Filing Date: 2025-01-21
Form Type: S-1/A
Source: 0001213900-25-004742
Chunk: 316

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-01-21
Form: S-1/A
Chunk 316
---
 splits, the number of shares of Series A Preferred Stock issuable upon the exercise of the Preferred
Warrant will also be adjusted so that the aggregate exercise price shall be the same immediately before and immediately after any such
adjustment.

The Preferred Warrants will expire on the first
anniversary of the closing of the Merger, or February 14, 2025.

We have the right, conditional upon the share price of CERO stock to be trading above $ 100.00per share, to require the holders of Preferred Warrants to exercise such Preferred Warrants into up to an aggregate number of shares of Preferred Stock equal to the holder’s pro rata amount of 2,500shares of Preferred Stock. In connection with the Series C PIPE Financing, we agreed with certain holders of the Preferred Warrants not to exercise such right to require such exercise by the holders thereof in consideration for their investment in the Series C PIPE Financing.

The Preferred Warrants prohibit us from entering
into specified fundamental transactions unless the Successor assumes all of our obligations under the Preferred Warrants under a written
agreement before the transaction is completed. Upon specified corporate events, a holder of the Preferred Warrants will thereafter have
the right to receive upon an exercise such shares, securities, cash, assets or any other property whatsoever which the holder would have
been entitled to receive upon the happening of the applicable corporate event had the Preferred Warrant been exercised immediately prior
to the applicable corporate event.

In the three-month period ended September 30,
2024, Series A Preferred Warrants were converted into shares of Series A Preferred Stock for proceeds of $.

The Company’s Preferred Warrants are exercisable
into Series A Preferred Stock, which has no cash redemption features that require liability treatment. The Company has recorded the Preferred
Warrants as equity.

|                                                 |     | Balance       
 September 30, 
 2024          |        |
|:------------------------------------------------|:----|:--------------|-------:|
| Common Warrants                                 |     |               |        |
| Preferred Warrants (Predecessor)                |     |               |      - |
| Public Warrants (Successor)                     |     |               | 91,925 |
| Conversion Warrants (Successor)                 |     |               |  3,250 |
| Common February 2024 PIPE Warrants (Successor)  |     |               |  6,127 |
| Common September 2024 PIPE Warrants (Successor) |     |